Skip to main content

Table 4 Responders’ median number of IL-2 doses by cycle and diagnosis*

From: Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal cancer in a Community Hospital Biotherapy Program

Cycle

Melanoma

Renal cancer

 

N

Median # doses

N

Median # doses

1

86

12

44

11

2

86

10

44

8

3

84

10

43

9

4

84

7

43

5

5

58

8

23

6

6

55

4

18

4

  1. *One responding patient with RCC received 8 cycles.
Back to article page